Gensight Biologics SA Stock
Price
Target price
€0.091
€0.091
-2.870%
-0.0027
-2.870%
-
12.12.25 / Stuttgart Stock Exchange
WKN: A2ANGZ / Name: Gensight / Stock / Biotechnology & Medical Research / Micro Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Gensight Biologics SA Stock
A loss of -2.870% shows a downward development for Gensight Biologics SA.
Our community identified positive and negative aspects for Gensight Biologics SA stock for the coming years. 1 users see the criterium "Worthwhile Investment for the next years" as a plus for the Gensight Biologics SA stock. On the other hand our users think that "Worthwhile Investment for the next years" could be a problem in the future.
Pros and Cons of Gensight Biologics SA in the next few years
Pros
?
M***** P*******
?
S********** s********
?
C******** o* t** e**********
Cons
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Gensight Biologics SA vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Gensight Biologics SA | -2.870% | -7.591% | -19.912% | -70.066% | -65.805% | -97.465% | -98.539% |
| Protara Therapeutics Inc. | 4.170% | 6.383% | 12.108% | -13.043% | -2.913% | 77.305% | -71.910% |
| India Globalization Capital | -3.520% | 14.167% | -9.868% | -22.159% | -18.452% | -18.136% | -79.865% |
| BioInvent International AB | 0.000% | -1.961% | -8.925% | -28.161% | -24.699% | -22.958% | -35.317% |
Comments
News
GenSight Biologics Announces Publication on Predictors of Final Visual Outcome in Patients Treated with LUMEVOQ® Gene Therapy
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal
GenSight Biologics Reports Cash Position as of June 30, 2025
Regulatory News:
GenSight Biologics ("GenSight Biologics" or the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing
GenSight Biologics Announces Significant Milestone in New Manufacturing Partnership with Catalent
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal